地诺单抗适用于哪些病症？

It is the first approved monoclonal antibody that specifically targets RANK ligand and is a bone resorption inhibitor with a unique mechanism of action. With the advancement of medical technology, the therapeutic potential of denosumab has also been exploited by overseas medical treatments. So, what conditions is denosumab suitable for?

Denosumab is approved for the treatment of breast cancer and for the prevention of bone-related events in solid tumors with bone metastases, except in patients with multiple myeloma. Instructions for use: 120mg, once every 4 weeks. Simultaneous infusion of calcium or vitamin D to prevent hypocalcemia; unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications. Instructions for use: 120 mg, once every 4 weeks, and add 120 mg on the 8th and 15th days of treatment in the first month of treatment; this drug is not suitable for use in patients with multiple myeloma to prevent skeletal-related events due to hypercalcemia in bisphosphonate-resistant malignant tumors.

Approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein, it is a bone resorption inhibitor with a unique mechanism of action. It specifically targets the receptor activator of nuclear factor kappa B (RANK) ligand and can inhibit osteoclast activity, thereby reducing bone resorption and increasing bone density. Originally approved for the treatment of postmenopausal osteoporosis, denosumab's indications have now been expanded to include other common metabolic bone diseases, including osteoporosis in men, glucocorticoid-induced osteoporosis, and bone loss due to aromatase inhibitor treatment in women with breast cancer, in addition to Yes, bone loss caused by androgen deprivation therapy in men with prostate cancer, skeletal-related events (bone pain and fractures) in multiple solid myeloma, giant cell tumors of bone, and hypercalcemia in malignancies all have RANK/RANKL (RANK ligand)/osteoprotegerin imbalances.